Windtree Therapeutics INC /DE/

Eric L. Curtis has resigned as President and Chief Operating Officer of Windtree Therapeutics, Inc., effective January 5, 2026.

Windtree Therapeutics issued $857,142.86 in senior convertible promissory notes to fund an acquisition and general corporate purposes.

Windtree Therapeutics, Inc. issued $1.6 million in senior convertible promissory notes to institutional investors, maturing in October 2026 with a 10% interest rate.

Windtree Therapeutics' subsidiary, WINT Real Estate, LLC, settled a dispute over a terminated real estate purchase agreement, recovering $750,000 of the $3 million earnest money.

Windtree Therapeutics announces the immediate resignation of its Senior Vice President and Chief Medical Officer, Steven G. Simonson, M.D.

Windtree Therapeutics stockholders approved all nine proposals at a Special Meeting, including significant share issuances, an increase in authorized capital, and a reverse stock split.

Windtree Therapeutics reported a significant net loss of $42.8 million for the nine months ended September 30, 2025, alongside a Nasdaq delisting and substantial doubt about its ability to continue as a going concern.

Windtree Therapeutics reported significant losses and a going concern warning, while announcing a new strategy to acquire revenue-generating products and launch a crypto treasury strategy.

Windtree Therapeutics reports a net loss of $4.0 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also pursuing a new revenue-generating acquisition strategy.

Windtree Therapeutics' Q3 2024 report details a net loss of $2.7 million, significant financial restructuring, and positive clinical trial results for istaroxime.

Windtree Therapeutics reports a net loss of $1.8 million for the six months ended June 30, 2024, while securing new financing to extend operations into October 2024.

Windtree Therapeutics reported a net income of $10.2 million for Q1 2024, primarily driven by a significant gain on debt extinguishment, while also highlighting ongoing clinical development efforts.

Windtree Therapeutics reports its 2024 10-K filing, highlighting financial uncertainties alongside progress in its cardiovascular and oncology programs.

Windtree Therapeutics undertakes several corporate actions including charter amendments, preferred stock issuance, and convertible note offerings to support its ongoing development programs.

Craig Fraser, CEO of Windtree Therapeutics, recently purchased 5,431 shares of the company's common stock at a price of $0.9099 per share.

SVP and Chief Medical Officer of Windtree Therapeutics, Steven Simonson, reports acquisition of Series C Preferred Stock and warrants in a private placement.

Windtree Therapeutics' CEO, Craig Fraser, acquired 19 shares of Series C Convertible Preferred Stock and 4,011 warrants in a private placement.

Windtree Therapeutics seeks shareholder approval for significant capital raises, a reverse stock split, and increased authorized shares to support operations and maintain Nasdaq listing.

Windtree Therapeutics is asking stockholders to approve a reverse stock split and an increase in the number of shares available under its equity incentive plan at a special meeting on February 3, 2025.

Windtree Therapeutics is holding its 2024 Annual Meeting of Stockholders virtually on September 24, 2024, to vote on director elections, executive compensation, auditor ratification, and approval of common stock issuances related to financing agreements.

Windtree Therapeutics is asking stockholders to approve a reverse stock split to increase its stock price and meet Nasdaq's continued listing requirements.

Windtree Therapeutics, Inc. has been delisted from Nasdaq, faces substantial doubt about its ability to continue as a going concern, and is pivoting to a new strategy focused on acquiring revenue-generating FDA-approved products.

Windtree Therapeutics, a biotechnology company, has filed an S-1/A registration statement to allow selling stockholders to resell up to 62.6 million shares of common stock, with the company not receiving any proceeds from these sales, while facing substantial doubt about its ability to continue as a going concern.

Windtree Therapeutics, a biotechnology company, filed an S-1/A to register the resale of up to 42.17 million common shares by selling stockholders, while pursuing a new corporate strategy focused on acquiring revenue-generating FDA-approved products and advancing its clinical pipeline, despite significant accumulated deficits and ongoing capital requirements.

Windtree Therapeutics is registering for the resale of up to 42,168,035 shares of its common stock, issuable upon conversion of Series D convertible preferred stock held by selling stockholders.

Windtree Therapeutics is registering up to 31,247,383 shares of common stock for resale by selling stockholders, including shares issuable upon conversion of preferred stock, exercise of warrants, and under an equity line of credit agreement.

Windtree Therapeutics is registering for resale up to 31.2 million shares of common stock by selling stockholders, including shares issuable upon conversion of preferred stock and notes, exercise of warrants, and under an equity line of credit.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 2.55% in Windtree Therapeutics, Inc. as of December 31, 2024.